Kiniksa Pharmaceuticals, Ltd.
We are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. We have a pipeline of product candidates across various stages of development, currently focused on autoinflammatory and autoimmune conditions. We have three clinical-stage product candidates, one of which is anticipated to commence a Phase 3 clinical trial in 2018.
|Address||Clarendon House, 2 Church Street, Hamilton HM11, Bermuda|
|Phone Number||(441) 295-5950|
|View Prospectus:||Kiniksa Pharmaceuticals, Ltd.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-75.9 mil (last 12 months)|
|Price range||$18.00 - $18.00|
|Est. $ Volume||$152.6 mil|
|Manager / Joint Managers||Goldman Sachs/ J.P. Morgan|
|CO-Managers||JMP Securities/ Wedbush PacGrow|
|Expected To Trade:||5/24/2018|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|